Pro-Pharmaceuticals To Present At Annual Glycobiology Conference

Targeting Tumor Lectins, DAVANAT® Shows Promising Results in Phase l Trial with 5-FU Refractory Patients.

Newton, Mass. (November 11, 2005) -- Pro-Pharmaceuticals, Inc. (Amex: PRW), a developer of novel carbohydrate compounds that enable the targeted delivery of chemotherapy drugs to cancer cells, today announced that Eliezer Zomer, Ph.D., Executive Vice President of Product Development and Manufacturing, Pro-Pharmaceuticals, will present in an abstract and a poster, “Targeting Tumor Lectins, Galactomannan Derivative Shows Promising Results in Pre-Clinical Studies and Phase l Clinical Trial With 5-FU Refractory Patients,” at the Annual Conference of the Society for Glycobiology, November 9-12, at The Boston Park Plaza Hotel, Boston, Mass.

The abstract is authored by David Platt, Ph.D., Chief Executive Officer and co-founder, Pro-Pharmaceuticals; Anatole Klyosov, Ph.D., D.Sc., Consulting Chief Scientist and co-founder, Pro-Pharmaceuticals, and Eliezer Zomer, Ph.D., Executive Vice President, Product Development & Manufacturing, Pro-Pharmaceuticals. A copy of the Abstract can be found at www.glycobiology.org.

“This data indicates DAVANAT® exhibits broad spectrum enhancement of anti-tumor drugs, including 5- Fluorouracil (5-FU), Irinotecan, and AVASTIN® in human colon and breast tumors. Data from the recently completed Phase I trial that evaluated advanced patients with a median tumor load of more than 100mm indicates the potential benefit of DAVANAT® in 5-FU refractory patients,” said Eliezer Zomer, Ph.D. “We are encouraged with the anti-tumor activity of DAVANAT® /5-FU and look forward to confirming the benefit of this combination therapy in Phase II/lll trials for colorectal cancer and cholangiocarcinoma.”

Society for Glycobiology Conference
The Society for Glycobiology is a nonprofit scholarly society devoted to the pursuit of knowledge of glycan structures and functions, and to the sharing of that knowledge among scientists worldwide. The official journal of the Society is Glycobiology. The objectives of The Society for Glycobiology shall be to promote knowledge, encourage research, and to stimulate personal communications, in an inter-disciplinary sense, using as a common meeting ground an interest in the complex carbohydrates of glycoproteins, glycolipids, glycosaminoglycans, and the biological systems in which they are found.

Phase lll Colorectal Cancer Trial
The Company received clearance from the European Medicines Agency (EMEA) to initiate a European Phase lll clinical trial for second line treatment of patients with metastatic colorectal cancer. The trial will be conducted at clinical sites in the European Union (EU) and countries outside of the EU following regulatory and ethics approval in each country. The Company expects to begin patient enrollment in the first quarter of 2006.

Phase II Colorectal Cancer Trial
The Company has an ongoing Phase II clinical trial of DAVANAT®/5-FU for third or fourth line treatment of colorectal cancer patients that are refractory to 5-FU. To date, 10 patients have been dosed at three clinical sites. Additional information is available at www.clinicaltrials.gov.

Phase ll Cholangiocarcinoma Trial
The Company submitted a clinical protocol to the U.S. Food & Drug Administration (FDA) in September for a Phase II study of its lead carbohydrate compound DAVANAT® with chemotherapeutic agent 5-FU for first line treatment of patients with cholangiocarcinoma (cancer of the bile duct). In May of this year, the FDA approved an application for a “compassionate use” Investigational New Drug to continue treating a patient for cholangiocarcinoma with liver metastases who participated in the Company’s Phase l trial. The patient has been treated for 12 months and continues to respond well. The Company expects to begin patient enrollment in the first quarter of 2006.

About DAVANAT®
DAVANAT® is a proprietary polysaccharide polymer comprised of mannose and galactose carbohydrates in a CARBOSOME™ formation that enables the target delivery of chemotherapy drugs to protein receptors (lectins) on cancer cells.

Pro-Pharmaceuticals, Inc. – Advancing Drugs Through Glycoscience®
Pro-Pharmaceuticals is a drug development company commercializing a new generation of anti-cancer treatments using carbohydrate compounds to Glyco-Upgrade™ the safety and efficacy of FDA-approved chemotherapy drugs by target delivering the drug to cancer cells. The Company has been conducting pre-clinical studies with 5-fluorouracil, irinotecan, doxorubicin, oxaliplatin, paclitaxel, cisplatin, and bevacizumab both in combination with DAVANAT® as well as other polysaccharide compounds. Human colon and breast xenography are being used to optimize formulations and results show that DAVANAT® exhibits a broad spectrum of activity with tested drugs. Additional information is available at www.pro-pharmaceuticals.com.

FORWARD LOOKING STATEMENTS: Any statements in this news release about future expectations, plans and prospects for the Company, including without limitation statements containing the words “believes,” “anticipates,” “plans,” “expects,” and similar expressions, constitute forward-looking statements as defined in the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Because of uncertainties and risks facing the Company, many of which are outside of the Company’s control, future events could cause actual results to differ materially from those indicated by such statements. More information about those risks
and uncertainties is contained and discussed in the “Management Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors” sections of the Company’s most recent quarterly or annual report and in the Company’s other reports filed with the Securities and Exchange Commission. The forward-looking statements herein represent the Company’s views as of the date of this news release and should not be relied upon to represent the Company’s views as of a subsequent date. While the Company anticipates that subsequent events may cause the Company’s views to change, the Company disclaims any obligation to update such forward-looking statements.

Contact: Pro-Pharmaceuticals, Inc., Anthony D. Squeglia: 617.559.0033; squeglia@pro-pharmaceuticals.com.

DAVANAT and Advancing Drugs Through Glycoscience are registered trademarks of Pro-Pharmaceuticals. Glyco-Upgrade and CARBOSOME are trademarks of Pro-Pharmaceuticals.

Contact Information

Anthony D. Squeglia

Media Contact

Pro-Pharmaceuticals, Inc.

Contact via E-mail